MedTrace Logo

HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor

NCT05787535 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2024-02-02

No results posted yet for this study

Summary

A single center, open, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of HRYZ-T101 TCR-T cell for HPV18 positive advanced solid tumor. The study will investigate DLT of HRYZ-T101 TCR-T cell injection.

Conditions

Interventions

DRUG

Fludarabine + Cyclophosphamide

Fludarabine: 25mg/m²/day×3days; Cyclophosphamide: 250mg/m²/day×3 days

BIOLOGICAL

HRYZ-T101 TCR-T Cell

On day 1, the TCR-T cells will be administered one time.

Sponsors & Collaborators

  • HRYZ Biotech Co.

    lead INDUSTRY

Principal Investigators

  • Jian Zhang, Doctor · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-21
Primary Completion
2025-02-28
Completion
2025-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05787535 on ClinicalTrials.gov